For the current week, the overall ratings of seven Biotechnology stocks are worse, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Genomic Health, Inc. (NASDAQ:GHDX) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. GHDX also rates an F in Portfolio Grader’s specific subcategory of Earnings Revisions. For more information, get Portfolio Grader’s complete analysis of GHDX stock.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) experiences a ratings drop this week, going from last week’s C to a D. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. For a full analysis of ACOR stock, visit Portfolio Grader.
Amarin Corporation Plc Sponsored ADR’s (NASDAQ:AMRN) rating weakens this week, dropping to a D versus last week’s C. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. In Earnings Growth, Earnings Revisions, Equity, and Cash Flow the stock gets F’s. As of Nov. 13, 2013, 18.9% of outstanding Amarin Corporation Plc Sponsored ADR shares were held short. To get an in-depth look at AMRN, get Portfolio Grader’s complete analysis of AMRN stock.
Exelixis, Inc. (NASDAQ:EXEL) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. The stock price has fallen 7.9% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. As of Nov. 13, 2013, 22.9% of outstanding Exelixis, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of EXEL stock.
Trius Therapeutics, Inc. (NASDAQ:TSRX) earns a D this week, falling from last week’s grade of C. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.
This is a rough week for Discovery Laboratories, Inc. (NASDAQ:DSCO). The company’s rating falls to D from the previous week’s C. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. For a full analysis of DSCO stock, visit Portfolio Grader.
The rating of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) slips from a C to a D. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also rates an F in Equity. Wall Street appears to agree with the stock downgrade, with share prices dropping 12% over the past month. As of Nov. 13, 2013, 19.5% of outstanding Achillion Pharmaceuticals, Inc. shares were held short. To get an in-depth look at ACHN, get Portfolio Grader’s complete analysis of ACHN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
